BioNTech posts Phase I results for BNT331 in bacterial vaginosis trial
Results from a completed first-in-human study of vaginal insert BNT331 in healthy women and women with bacterial vaginosis were posted on October 5, 2026.
BioNTech SE had one trial update of note this week.
- "A First-in-human Safety Trial of BNT331" (NCT06469164), a Phase I study in healthy women and women diagnosed with bacterial vaginosis, is listed as completed, with a randomized, double-blind, placebo-controlled design assessing safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of BNT3311. The study enrolled 102 participants1, and results were first posted on 2026-10-05 per the registry record.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.